18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma

Digestive and Liver Disease

Volumn 44, Issue 10, 2012, Pages 875-879

  Di Fiore, Frederic ^a   Blondin, Valérie ^a   Hitzel, Anne ^a   Edet Sanson, Agathe ^a   Benyoucef, Ahmed ^a   Huet, Emmanuel ^a   Vera, Pierre ^a   Michel, Pierre ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

Chemoradiotherapy; Oesophageal cancer; Outcome; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS;

EID: 84865760934     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.04.017     Document Type: Article

References (28)

1. Keighley M.R.B. Gastrointestinal cancers in Europe. Pharmacology & Therapeutics 2003, 18:7-30.
2. Enzinger P.C., Mayer R.J. Oesophageal cancer. New England Journal of Medicine 2003, 349:2241-2252.
3. Fink U., Stein H.J., Bochtler H., et al. Neoadjuvant therapy for squamous cell oesophageal carcinoma. Annals of Oncology 1994, 5(Suppl. 3):17-26.
4. Courrech Staal E.F.W., Aleman B.M.P., Boot H., et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. British Journal of Surgery 2010, 97:1482-1496.
5. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 09102. Journal of Clinical Oncology 2007, 25:1160-1168.
6. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. Journal of Clinical Oncology 2005, 23:2310-2317.
7. Sarkaria I.S., Rizk N.P., Bains M.S., et al. Post-treatment endoscopic biopsy is a poor predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Annals of Surgery 2009, 249:764-767.
8. Yang Q., Cleary K.R., Yao J.C., et al. significance of post chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Diseases of the Esophagus 2004, 17:38-43.
9. Jones D.R., Parker L.A., Detterbeck F.C., Egan T.M. Inadequacy of computed tomography in assessing patients with oesophageal carcinoma after induction chemoradiotherapy. Cancer 1999, 85:1026-1032.
10. Michel P., Adenis A., Di Fiore F., et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. British Journal of Cancer 2006, 95:705-709.
11. Seitz J.F., Milan C., Giovannini M., et al. Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803). Gastroenterologie Clinique et Biologique 2000, 24:201-210.
12. Brücher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of oesophageal squamous cell carcinoma: response evaluation by positron emission tomography. Annals of Surgery 2001, 233:300-309.
13. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Annals of Oncology 2002, 13:361-368.
14. Kato H., Kuwano H., Nakajima M., et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with oesophageal cancer. American Journal of Surgery 2002, 184:279-283.
15. Arslan N., Miller T.R., Dehdashti F., et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2{18F}fluoro-d-glucose with positron emission tomography in patients with oesophageal cancer. Molecular Imaging and Biology 2002, 4:301-310.
16. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of oesophageal cancer to induction therapy: results of a prospective trial. Journal of Clinical Oncology 2003, 21:428-432.
17. Song S.Y., Kim J.H., Ryu J.S., et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable oesophageal cancer. International Journal of Radiation Oncology, Biology, Physics 2005, 63:1053-1059.
18. Levine E.A., Farmer M.R., Clark P., et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced oesophageal cancer. Annals of Surgery 2006, 243:472-478.
19. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with oesophageal carcinoma. Cancer 2004, 101:1776-1785.
20. Duong C.P., Hicks R.J., Weih L., et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging 2006, 33:770-778.
21. Monjazeb A.M., Riedlinger G., Akilu M., et al. Outcomes of patients with oesophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection. Journal of Clinical Oncology 2010, 28:4714-4721.
22. Murthy S.B., Patnana S.V., Xiao L., et al. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology 2010, 78:316-322.
23. Suzuki A., Xia L., Hayashi Y., et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with oesophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011, 10.1002/cncr.26122.
24. Lordick F., Ott K., Krause B.J. New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Annals of Oncology 2010, 21(Suppl. 7):vii294-vii299.
25. Kim M.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in esophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. European Journal of Cancer 2007, 43:1385-1391.
26. Tougeron D., Di Fiore F., Hamidou H., et al. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology 2007, 73:328-334.
27. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet Oncology 2006, 368:843-854.
28. Francois Y., Nemoz C.J., Baulieux J., et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer. the Lyon R90-01 randomized trial. Journal of Clinical Oncology 1999, 17:2396-2402.